Lonza readies for ‘new wave of ADC therapies’ with Visp expansion

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Anyaberkut)
(Image: Getty/Anyaberkut)

Related tags: Switzerland, Lonza, Antibody drug conjugates

Lonza already manufacturers three out of five commercially available ADCs but is preparing for additional demand with a two-year expansion project at its Visp site.

Lonza, a contract development and manufacturing organization (CDMO), began the expansion of its bioconjugation facility in Visp, Switzerland. The site will be completed by 2020 and will hold all elements of antibody-drug conjugate (ADC) production in a single site.

At the same time  as the expansion announcement, Lonza confirmed that its Visp site had completed a successful inspection by the US Food and Drug Administration (FDA) for the commercial manufacture of an unnamed ADC.

The product becomes the third ADC manufactured at the site, with commercial manufacture of the ADC met by existing capacity. The two-year expansion project is being carried out to meet anticipated further demand.

Karen Fallen, head of mammalian and microbial development and manufacturing at Lonza, said, “With 11 investigational new drugs (INDs) completed, and now three out of five commercially available ADCs supported by our bioconjugation facility, we see the need to expand in readiness for the new wave of therapies our customers are developing.”

In addition, the expansion will be able to cover the range of manufacturing, from early clinical phase to commercial manufacture.

Fallen continued, “Many bioconjugates are on expedited programs and the existing expertise at the facility, combined with proximity to clinical and commercial manufacturing of antibody, linkers and payload, will reduce risk and increase speed on the path to market.”

In particular, Thomas Rohrer, head of commercial development bioconjugates at Lonza, stated that the third ADC that will be produced as the site had received accelerated approval. This meant that handling its development in one site helped the CDMO meet the ‘tight deadline’ involved for successful validation of the manufacturing process.

Lonza has previously invested in its manufacturing sites​ at the location to be able to simplify the ADC supply chain, by manufacturing intermediates and drug substances under one system.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars